Wolverine Trading
CRSP icon

Wolverine Trading’s CRISPR Therapeutics CRSP Stock Holding History

Wolverine Trading’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-113,000
Closed -$4.18M – 4905
2025
Q1 		$4.18M Buy
113,000
+19,800
+21% +$839K ﹤0.01% 1090
2024
Q4 		$3.6M Buy
93,200
+24,700
+36% +$1.17M ﹤0.01% 1462
2024
Q3 		$3.24M Hold
68,500
– – ﹤0.01% 1340
2024
Q2 		$3.7M Sell
68,500
-5,800
-8% -$335K ﹤0.01% 1159
2024
Q1 		$5.06M Sell
74,300
-30,800
-29% -$2.2M 0.01% 1019
2023
Q4 		$6.58M Buy
105,100
+36,300
+53% +$2.01M 0.01% 924
2023
Q3 		$3.12M Buy
68,800
+4,700
+7% +$243K ﹤0.01% 1292
2023
Q2 		$3.65M Buy
64,100
+12,700
+25% +$721K ﹤0.01% 1090
2023
Q1 		$2.27M Sell
51,400
-15,200
-23% -$738K ﹤0.01% 1292
2022
Q4 		$2.71M Sell
66,600
-1,000
-1% -$53K ﹤0.01% 1215
2022
Q3 		$4.36M Sell
67,600
-1,700
-2% -$123K 0.01% 915
2022
Q2 		$4.37M Sell
69,300
-4,800
-6% -$282K 0.01% 866
2022
Q1 		$4.75M Sell
74,100
-12,500
-14% -$785K 0.01% 1103
2021
Q4 		$6.83M Buy
86,600
+11,400
+15% +$996K 0.01% 944
2021
Q3 		$8.29M Sell
75,200
-11,800
-14% -$1.48M 0.01% 934
2021
Q2 		$13.1M Sell
87,000
-2,600
-3% -$316K 0.02% 587
2021
Q1 		$10.3M Buy
89,600
+29,000
+48% +$4.38M 0.02% 678
2020
Q4 		$9.79M Buy
60,600
+31,000
+105% +$3.66M 0.02% 684
2020
Q3 		$2.52M Sell
29,600
-2,300
-7% -$204K 0.01% 1305
2020
Q2 		$2.39M Buy
31,900
+9,000
+39% +$526K 0.01% 1281
2020
Q1 		$1.01M Buy
22,900
+200
+0.9% +$10.3K ﹤0.01% 1916
2019
Q4 		$1.4M Sell
22,700
-16,500
-42% -$901K ﹤0.01% 2112
2019
Q3 		$1.66M Sell
39,200
-13,600
-26% -$650K ﹤0.01% 1563
2019
Q2 		$2.49M Buy
52,800
+12,100
+30% +$484K 0.01% 1352
2019
Q1 		$1.45M Sell
40,700
-1,500
-4% -$51.9K ﹤0.01% 1778
2018
Q4 		$1.13M Buy
42,200
+24,500
+138% +$852K ﹤0.01% 1867
2018
Q3 		$785K Buy
+17,700
New +$927K ﹤0.01% 2607

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wolverine Trading's CRSP Position: Q2 2025 in Review

Wolverine Trading sold out of CRISPR Therapeutics (CRSP) in Q2 2025, closing a stake of 21,081 shares — an estimated $780K sold.

Wolverine Trading first reported a position in CRSP in Q3 2018 and held it in 23 quarters. The position peaked at $7.5M in Q2 2021. 433 funds tracked by Wall St. Rank hold CRSP as of Q2 2025.

  • Wolverine Trading reported no remaining CRISPR Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Wolverine Trading sold 21,081 CRISPR Therapeutics shares in Q2 2025, an estimated $780K.
  • Wolverine Trading first reported a position in CRISPR Therapeutics in Q3 2018 and held it in 23 quarters.
  • Wolverine Trading's CRISPR Therapeutics position peaked at $7.5M in Q2 2021.
  • 433 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2025.

Based on Wolverine Trading's 13F filing for Q2 2025, filed 18 Aug 2025.